Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

Rahway: Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, have announced that the Biologics ...

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly ...

In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

PFS in Phase 3 HARMONi study was met with statistical significance, but OS was not. Click here to find out why SMMT stock is ...

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...

Dana-Farber Cancer Institute investigators launch a first-of-its kind study to use a novel blood test to identify people who ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat.